Mode
Text Size
Log in / Sign up

Mixed endometrial carcinoma

Part of Cancer

1 published article · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

Systematic review and meta-analysis of ML with cfDNA for cancer detection across stages
Radiology & Imaging Meta-analysis
Systematic review and meta-analysis of ML with cfDNA for cancer detection across stages Simple blood test spots early cancer without scary scans
This systematic review and meta-analysis of 109 articles synthesized diagnostic performance of machine learning with circulating cell-free D…
• AI analyzes blood fragments to catch hidden cancers early • Helps people avoid painful biopsies and late diagnoses • Still in labs not rea…
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier
Oncology Sys. Review
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier Precision oncology advances gynecologic cancer care but resistance remains a major barrier
This systematic review examined the current landscape of precision oncology for patients with endometrial, ovarian, and cervical carcinomas.
Molecular reclassification lets doctors use targeted drugs effectively for gynecologic cancers, but tumor evolution creates a major barrier …
Case report: Low-intensity chemotherapy achieves remission in PMF transformed to MPAL
Oncology Cohort
Case report: Low-intensity chemotherapy achieves remission in PMF transformed to MPAL Single case report describes treatment for rare leukemia transformation in elderly patient
A case report describes a 75-year-old female with JAK2V617F-positive primary myelofibrosis that transformed to mixed phenotype acute leukemi…
A 75-year-old woman with rare leukemia transformation from blood disorder achieved remission after two cycles of low-intensity chemotherapy.